Οδοντιατρείο Ιωάννης Ζερδές - Home | Facebook
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
Ioannis Zerdes - Oncology Resident - Karolinska University Hospital | LinkedIn
Editorial Board | ARC Journal of Cancer Science | High Impact Journals
Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
Ioannis Zerdes - Glifádha, Attiki, Greece | Professional Profile | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications | Semantic Scholar
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
TOKYO, JAPAN - AUGUST 8: Silver for team Greece with head coach Theodoros Vlachos of Greece, Emmanouil Zerdevas of Greece, Konstantinos Genidounias of Greece, Dimitrios Skoumpakis of Greece, Marios Kapotsis of Greece,
Οδοντιατρείο Ιωάννης Ζερδές - Home | Facebook
PDF) Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
